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ABSTRACT
Strigolactones are a novel class of plant hormones produced in roots that 
regulate shoot and root development. We previously reported that strigolactone 
analogs (SLs) induce G2/M cell cycle arrest and apoptosis in a variety of human 
cancer cells and inhibit tumor growth of human breast cancer xenografts in mice. SLs 
had no significant influences on non-transformed cells. Here we report for the first 
time that SLs induce DNA damage in the form of DNA double-strand breaks (DSBs) 
and activate the DNA damage response signaling by inducing phosphorylation of 
ATM, ATR and DNA-PKcs and co-localization of the DNA damage signaling protein, 
53BP1, with γH2AX nuclear foci. We further report that in addition to DSBs induction, 
SLs simultaneously impair DSBs repair, mostly homology-directed repair (HDR) and 
to a lesser extent non-homologous end joining (NHEJ). In response to SLs, RAD51, 
the homologous DSB repair protein, is ubiquitinated and targeted for proteasomal 
degradation and it fails to co-localize with γH2AX foci. Interestingly, SLs synergize 
with DNA damaging agents-based therapeutics. The combination of PARP inhibitors 
and SLs showed an especially potent synergy, but only in BRCA1-proficient cells. No 
synergy was observed between SLs and PARP inhibitors in BRCA1-deficient cells, 
supporting a role for SLs in HDR impairment. Together, our data suggest that SLs 
increase genome instability and cell death by a unique mechanism of inducing DNA 
damage and inhibiting DNA repair.
INTRODUCTION
Cancer remains the second-leading cause of death 
in the United States. Treatment of advanced disease with 
classical chemotherapeutic drugs is completely successful 
in only several  types of cancer such as testicular 
carcinoma and childhood leukemia [1]. In most other 
types of cancer, despite an initial favorable response, 
local and distant relapses associated with resistance to 
chemotherapy invariably occur and thus result in limited 
survival benefits [1]. Therefore, the development of safe 
and effective drugs along with novel therapeutic strategies 
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that successfully eradicate tumors and metastatic growth 
are highly desirable. A challenge arises in identifying 
therapeutic combinations that will target both the 
hyperproliferative cells as well as the slow-growing 
cancer stem-like cells that are capable of self-renewal and 
survival after therapy. Moreover, productive  combinations 
may create synergistic responses permitting the use of 
the lowest possible drug dosages to effectively target all 
cancer cells and reduce toxic side effects [1-3].
Strigolactones are a novel class of phytohormones 
produced by a wide variety of plant species [4]. In 
plants, Strigolactones are involved in pleiotropic effects 
including endogenous control of above ground plant 
development via bud outgrowth repression and inhibition 
of shoot meristem [5]. Previously, we reported that small 
molecules, synthetic analogs of SLs, induce G2/M arrest 
and apoptosis in a variety of human cancer cells, but 
have minimal influence on growth and viability of non-
transformed human fibroblasts, mammary epithelial cells, 
as well as normal primary prostate cells [6, 7]. In vivo, 
SL analogs inhibit the growth of human MDA-MB-231 
xenografts [8]. Interestingly, cancer cells with stem-like 
properties are more sensitive to the inhibitory effects of 
SLs analogs than the heterogeneous population of cancer 
cells [6]. 
We showed that SLs’ inhibitory effects are 
associated with activation of the stress-activated MAPKs, 
P38 and JNK1/2, interference with the tubulin network, 
and inhibition of the survival factors, ERK1/2 and AKT 
[6-8]. Our current knowledge as to the exact mechanism 
of action, however, is limited. The activation of the 
stress response led us to hypothesize that SLs induce 
DNA damage and genomic instability. Double-strand 
breaks (DSBs) are considered the most deleterious form 
of DNA damage and DSBs repair is essential for tumor 
cell survival [9, 10]. There are two major pathways of 
DSBs repair: an error-prone non-homologous end joining 
(NHEJ) that often includes processing of the DNA broken 
ends before ligation, and the error-free homology-directed 
repair (HDR) that uses a homologous sequence (most 
often a sister chromatid) as a template for repair [11-
13]. While cells employ NHEJ throughout the cell cycle, 
HDR is utilized only during S and G2 phases [12]. Cells 
with compromised HDR are prone to synthetic lethality 
when triggered by DNA-damaging agents. This has been 
exemplifed in BRCA1- and BRCA2-mutated tumors 
treated with PARP inhibitors [14-18] or platinum-based 
chemotherapy [14, 19, 20]. RAD51 is another critical 
component of the HDR machinery. RAD51 assembly 
onto single-stranded DNA ends catalyzes the exchange of 
homologous DNA sequences at the break sites [10, 21]. 
Suppression of RAD51 sensitizes cancer cells to DNA-
damaging drugs [10, 22-25], and RAD51 overexpression 
contributes to chemotherapy resistance in several types 
of cancer including breast, prostate and human soft tissue 
sarcoma cells [10, 26-31].
In the present study, which confirms the selective 
anti-proliferative effect of SLs in cancer cells, we establish 
that SLs induce DSBs and inhibit their repair by HDR 
and NHEJ. We further show that SLs down regulate the 
expression of RAD51 in a proteasome-dependent manner 
and inhibit RAD51 re-localization to DSB sites. Together, 
our studies suggest that by inducing a “BRCAness” 
phenotype, SLs can sensitize cells to chemotherapeutic 
drugs such as PARP inhibitors to enhance their efficacy. 
RESULTS
Strigolactones induce apoptosis in U2OS 
osteosarcoma cells
We previously reported that synthetic analogues of 
strigolactones (SLs) (Figure 1A) reduce the viability of a 
variety of cancer cells [6, 7]. To assess whether SLs induce 
cell cycle arrest or cell death in the U2OS osteosarcoma 
cell line, we stained the cells with propidium iodide 
(PI) and examined cell cycle progression by FACS. A 
significant increase in the percentage of U2OS cells in 
G2/M and sub-G1 phases was detected at 24 and 48 hr 
after treatment with the strigolactone analogs MEB55 or 
ST362 (Figure 1B). To further assess the impact of SLs 
on cell death, dual staining with Annexin V and PI was 
employed. Annexin V is a marker of early apoptosis, 
while PI stains cells in late apoptosis with a compromised 
plasma membrane. A significant increase in early and 
late apoptosis was detected in U2OS cells after 24 hr 
treatment with either MEB55 or ST362 (Figure 1C and 
Supplementary Figure S1). An increase in caspase 3/7 
activity was detected as early as 8 hours after treatment 
with MEB55 and further corroborated the induction of 
MEB55-mediated apoptotic cell death (Figure 1D). 
Strigolactones induce genomic instability and 
DNA double-strand breaks
Next, we examined the possibility that cellular 
responses to SLs are associated with DNA damage and 
loss of genomic stability. Metaphase spreads of U2OS 
cells were prepared and stained with DAPI after treatment 
with 5 or 10 ppm of MEB55 or ST362 for 24 hr. U2OS 
osteosarcoma cells contain chromosome counts in the 
hypertriploid range; the average chromosome count 
in untreated cells displaying long intact chromosomes 
(Figure 2A) is 113±7.3 chromosomes per metaphase 
spread. Treatments with MEB55 or ST362 led to a 
significant increase in chromosome count (Figure 2A) 
with an average of 140±3.4 and 141±3.8 chromosomes per 
metaphase spread, respectively (***p < 0.0001) (Figure 
2B). 
The induction of DNA DSBs in SLs-treated 
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Figure 1: Strigolactone analogs induce G2/M arrest and apoptotic cell death. A. The chemical structure of synthetic analogs 
of strigolactone MEB55 (1 ppm = 3.1 µM) and ST362 (1 ppm = 2.1 µM) B. U2OS cells were treated with MEB55 or ST362 at 10 ppm for 
6, 24, and 48 hr, or with DMSO vehicle (V). Graph is representative of mean of three independent experiments. Cell cycle analysis was 
performed by flow cytometry (* p < 0.05; ** p ≤ 0.001). C. U2OS cells treated with MEB55 or ST362 at 10 ppm for 24 hr were stained 
with Annexin V/PI and analyzed relative to vehicle (DMSO)-treated cells by flow cytometry. Graph is representative of mean ± SD of at 
least three independent experiments. D. Caspase activation, as measured by Caspase-3/7 Glo luciferase assay of U2OS cells treated with 
MEB55 at 10 ppm for the indicated durations, relative to 24 hr vehicle-treated (DMSO) control cells. Graph is representative of mean ± SD 
of at least three independent experiments. (* p < 0.05; ** p ≤ 0.001). 
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cells was verified using the neutral Comet Assay, an 
electrophoretic method to measure DNA damage and 
the presence of DNA DSBs. Vehicle and MEB-treated 
cells at 10 ppm were harvested after 4 hr and visualized 
on Comet slides using SYBR green. The presence of 
“tails” projecting from the embedded cells indicates 
damaged DNA fragments that have migrated farther 
during electrophoresis. Images taken of the vehicle and 
treated cells indicate an increased presence of tails in the 
MEB55-treated cells (Figure 2C). Quantification of this 
observation using the CometScore program indicated a 
4-fold increase in tail moment in strigolactone-treated cell 
samples (***p < 0.0001) validating that SLs induce DSBs 
(Figure 2D). 
To determine whether SLs induce chromosome 
breakage via DNA crosslinking, we analyzed the 
chromosomes of lymphoblast cells derived from a 
Fanconi Anemia complementation group C (FANCC) 
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patient. Metaphase analysis demonstrates that the FANCC 
cells are highly sensitive to mitomycin C (MMC), a 
DNA crosslinking agent, that induces both chromosome 
crosslinking and DNA breaks. SLs caused a higher rate 
of chromosome breaks relative to control (1.4 breaks per 
cell in ST362-treated cells vs. 0.8 breaks /cell in control 
cells) (Figure 2E and 2F). However, no chromosomal 
crosslinking was observed in SL-treated cells (Figure 2E). 
Strigolactone treatment leads to activation of the 
DNA damage response in U2OS cells
To determine whether SLs treatment elicits 
activation of the DNA damage response (DDR), we 
analyzed the phosphorylation of the DNA DSBs marker, 
histone H2AX [32], in U2OS cells treated with 10 ppm 
of MEB55 or ST362 for 4 hr. Figure 3A shows that 
expression of γH2AX is induced in SLs-treated cells 
similar to cells exposed to 8 Gy of ionizing radiation 
(Figure 3B). We further analyzed the phosphorylation/
activation of the DNA damage sensors ATM, ATR, DNA-
PKcs and their downstream checkpoint kinases, Chk1 
and Chk2 [33-35]. U2OS cells were treated with either 
MEB55 or ST362 at 10 ppm for 4 hours or with 8 Gy of 
ionizing radiation (IR) as a positive control. Immunoblot 
analysis revealed that ATM, ATR and DNA-PKcs 
phosphorylation is induced in response to SLs, in addition 
to the phosphorylation of Chk1 and Chk2 kinases (Figure 
3B and Supplementary Figure S2). Moreover, we show 
that the well-established DSB marker, 53BP1, is recruited 
to DSB sites and co-localizes with γH2AX foci [36, 37] 
Figure 2: SLs induce DSBs and increase genomic instability. A. U2OS cells were treated with 5 or 10 ppm of MEB55 or ST362 
for 5 hr and subjected to metaphase spread assays to examine chromosome integrity. Representative images from at least 50 images are 
shown. B. Quantitative analysis of chromosomal breaks. The number of chromosomes per spread was counted from at least 50 spreads for 
each sample. The experiment was repeated at least three times and the data represent mean ± SD. (* p < 0.04; ** p ≤ 0.0004). C. U2OS cells 
were treated with vehicle (top panel) or MEB55 at 10 ppm (bottom panel) for 5 hr. The presence of DSBs is indicated by the Neutral Comet 
assay. D. Quantitative analysis of at least two independent experiments. At least 30 cells were scored. Values represent mean ±SD. (*** p 
< 0.0001). E. FANCC cells were treated with either vehicle control, 300 nM MMC or SLs at 10 ppm for 72 hrs and subjected to metaphase 
spreads. Representative images from at least 50 spreads are shown. F. The number of chromosomal aberrations in response to the different 
treatments (crosslinking and breakage) were quantified. Values represent mean +/- SD. (** P<0.001) .
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Figure 3: SLs activate the DNA damage response-signaling cascade. A. U2OS cells were treated with vehicle or 10 ppm of SLs 
(MEB55 or ST362) for 4 hr. Following histone extraction, expression levels of histone H2A and γH2AX were analyzed by immunoblot. 
B. Following treatment with 10 ppm of MEB55 or ST362, U2OS cells were lysed and expression levels of ATM, phosphorylated ATM, 
ATR and DNA-PKcs as well as phosphorylated Chk1 and Chk2 were analyzed by immunoblot. β-Actin was employed as a loading 
control. C. U2OS cells were treated with 10 ppm of ST362 or MEB55 for 3 hr or with 8 Gy ionizing radiation (IR) as a positive control. 
Immunofluorescent analysis indicates that 53BP1 co-localizes with γH2AX foci. D. Co-localization of 53BP1 and γH2AX in nuclear foci 
in DU145 prostate cancer cell line, patient-derived conditionally-reprogrammed prostate cancer cells (PP8T), or patient-derived prostate 
cancer organoid conditionally-reprogrammed PCA3 cells treated with 10 ppm of MEB55 or IR as positive control. E. γH2AX foci in U2OS 
and BJ fibroblasts in response to 8 Gy IR or 20 ppm ST362. 
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upon treatment with 10 ppm of ST362 (Figure 3C and 
supplementary Figure S3) or 10 ppm of MEB55 (Figure 
3D). 
53BP1 is also recruited to sites of DSBs together 
with γH2AX in DU145 prostate cancer cells, in a 
castration-resistant patient-derived organoid line termed 
CRPC-PCA3 [38] [7, 39, 40, 41], and in a patient-derived 
CRC line PP8T, from a patient diagnosed with Gleason’s 
score 8 prostate cancer (Figure 3E). Conversely, SLs failed 
to elicit γH2AX foci and DSBs in non-transformed BJ 
fibroblast cells (Figure 3E and Supplementary Figure S4).
Strigolactone analogs interfere with RAD51 
expression and co-localization to DSBs
We next analyzed whether the homologous repair 
protein, RAD51, co-localizes to the DSBs sites formed in 
response to SLs treatment [21, 34]. RAD51 recruitment to 
γH2AX sites indicates that cells have initiated DNA repair 
by HDR at the damaged sites [34]. Because SLs cause cell 
cycle arrest at the G2/M phase [6, 7], we hypothesized 
that HDR would be the main mechanism of DSBs repair. 
However, unlike 53BP1, RAD51 did not form distinct 
foci that co-localize with γH2AX foci in U2OS cells or 
in DU145 cells treated with 10 ppm MEB55 or ST362 
(Figure 4A). Moreover, immunoblot analysis revealed 
that RAD51 expression is down-regulated beginning 1 hr 
after treatment with 10 ppm of MEB55 and continues to 
decline by 5 hr. Pre-treatment of cells with 10 µM of the 
proteasome inhibitor, MG132, alleviated RAD51 down-
regulation by SLs (Figure 4B and 4C) and demonstrated 
that RAD51 becomes poly-ubiquitinated following SLs 
treatment (Figure 4D). Together, our data indicate that 
SLs target RAD51 for proteasomal degradation, thereby 
disrupting its redistribution onto sites of DSBs. 
Strigolactones inhibit DSB repair
The failure of RAD51 to co-localize with DSB 
sites after SLs treatment led us to hypothesize that DSBs 
repair is impaired in SLs-treated cells, which could be the 
mechanism leading to SLs-mediated cell death. DSBs can 
be repaired by homology-directed repair (HDR) or by non-
homologous end joining (NHEJ) [11, 13]. We utilized two 
well-characterized GFP-based reporter systems to gain 
insight into the mechanisms by which SLs inhibit DSBs 
repair. The HDR assay was based on U2OS cells that 
stably carry the direct repeat (DR)-GFP construct [42]. 
Following transfection of the I-SceI restriction 
enzyme expression plasmid (pCBAS), which cleaves 
the DR-GFP reporter construct, cells were treated with 
different concentrations of MEB55 for 24 hr. GFP 
fluorescence occurs only if the cell regains a complete 
GFP sequence by HDR as determined by FACS analysis 
(Figure 5A). A significant dose-dependent decrease 
in GFP fluorescence was observed following MEB55 
treatment as compared to control, vehicle-treated, cells 
(Figure 5B). Each concentration of MEB55 (2.5, 5, and 
10 ppm) showed a statistically significant decrease of 
about 42%, 60% and 90 % in GFP+ cells as compared 
with the control cells (**p ≤ 0.01, and ***p ≤ 0.0004, 
respectively). Given these results, we conclude that 
MEB55 inhibits the frequency of HDR in cancer cells, the 
preferable DSB repair pathway when cells are arrested in 
G2 phase. Interestingly, a previous report by Goldstein and 
Kastan also showed a 90% decrease in HDR upon RAD51 
depletion [43]. 
Next, we utilized a parallel reporter system to 
analyze the effect of MEB55 on NHEJ. The EJ5-GFP 
reporter construct is stably integrated into U2OS cells 
[44]. The reporter consists of two I-SceI sites flanking 
a puromycin resistance gene. Following transfection of 
the I-SceI expressing plasmid, pCBAS, the puro gene is 
excised upon the repair by NHEJ, allowing for recovery of 
the GFP gene and GFP expression (Figure 5C). EJ5-GFP 
cells transfected with pCBAS were treated with increasing 
concentrations of MEB55. At low concentrations (1-5 
ppm), MEB55 had no effect on NHEJ activity relative to 
vehicle-treated cells; MEB55 at 10 ppm, however, caused 
a 30% decrease in NHEJ activity (*p ≤ 0.025), suggesting 
that the NHEJ repair pathway is also compromised (Figure 
5D). Overall, these results suggest that SLs impair HDR 
and NHEJ repair mechanisms. 
Strigolactones do not intercalate into DNA, but 
sensitize cells to PARP inhibitors
To further elucidate the mechanisms by which 
SLs cause DSBs and interfere with their repair, we 
tested whether SLs intercalate into the DNA by an 
ethidium bromide (EtBr) displacement assay [45]. The 
fluorescence of EtBr is weak in aqueous solution, but its 
strong intercalation into the DNA greatly enhances its 
fluorescence intensity. Using cell-free circulating DNA 
(CT-DNA), we tested whether SLs can displace pre-
bound EtBr. Figure 6A shows that despite increasing 
concentrations (1.25 ppm-20 ppm) of MEB55 or ST362, 
there was no decrease in the emission intensity of EtBr, 
indicating that SLs do not displace or compete with EtBr 
(Figure 6A, 6B and Supplementary Figure S5). 
We next tested for additive or synergistic effects 
on growth inhibition when SLs were combined with 
doxorubicin (DOX), which intercalates into the DNA and 
causes DNA damage by inhibiting DNA topoisomerase II. 
The IC50 of DOX in U2OS cells (1.72 µM) was determined 
by XTT assay after 72 hr treatment (Supplementary 
Figure S6). Based on the method of non-constant ratio 
drug combination proposed by Chou and Talalay [46], 
XTT viability assays were carried out in non-constant 
ratios corresponding to 2 concentrations below and above 
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Figure 4: SLs affect RAD51 expression and function. A. RAD51 fails to co-localize with γH2AX foci. U2OS and DU145 cells 
were treated with ST362 or MEB55 at 10 ppm for 4 hr or with 8 Gy IR as a positive control and then stained for immunofluorescent analysis 
of RAD51 and γH2AX. B. SLs down regulate RAD51. U2OS cells were treated with 10 ppm of MEB55 for the indicated times or pre-
treated with MG132 at 10 µM 1 hr prior to MEB55 treatment. RAD51 expression was analyzed by immunoblot. β-Actin was employed 
as a loading control. The experiment was repeated at least three times. C. Quantification of normalized RAD51 relative to vehicle-treated 
cells. D. RAD51 is poly-ubiquitinated upon SLs-treatment. U2OS cells were pre-treated with 10 µM MG132 1 hr prior to treatment with 
10 ppm of MEB55 or vehicle. Three mg of whole cell lysates were incubated overnight at 4oC with a polyclonal antibody against RAD51 
and protein A/G. Ubiquitination was resolved by immunoblot with an antibody against poly-ubiquitined proteins (left panel) or RAD51 
(right panel). 
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the IC50 for each compound (Supplementary Figure S7). 
Combination index (C-Index) analyses of DOX and 
SLs were performed using the CompuSyn software and 
were based on the C-Index equation [46]. The effect 
levels (Supplementary Table 2) and data in Figure 6D 
illustrate C-Index values below (synergy), and above 
(antagonism) the 1 additivity line. Based on the C-Index 
values less than 1, partial synergy can be seen in three 
different combinations between DOX and MEB55 when 
concentrations of both compounds are below their IC50. 
In addition, SLs did not induce the typical DNA cleavage 
pattern produced by camptothecin or MJ-III-65, both 
of which are DNA topoisomerase I inhibitors (Figure 
6C) [47, 48]. Taken together, these results indicate it is 
unlikely that SLs cause DSBs through DNA intercalation 
and inhibition of topoisomerase I or II enzymes. 
Because cells deficient in HDR are sensitive to 
PARP inhibitors [9, 14], we tested whether SLs-treated 
cells with reduced RAD51 and HDR efficiency exhibit 
enhanced sensitivity to the commercially available PARP 
inhibitors (olaparib and veliparib). As expected, olaparib 
itself (with increasing concentrations up to 8 µM) did not 
affect U2OS cell viability, and veliparib alone affected cell 
viability only slightly at the highest concentrations of 40 
Figure 5: SLs impair Homology-Directed Repair of DNA DSBs. A. A schematic representation of the DR-GFP reporter assay. 
B. U2OS cells stably carrying the DR-GFP reporter were transfected with I-SceI expression plasmid and on the following day were treated 
with the indicated concentrations of MEB55 for 24 hr. GFP positive cells were quantified 24 hr later by FACS. Results represent mean 
± SD from at least three independent experiments. C. A schematic representation of the EJ5-GFP reporter assay. D. U2OS cells stably 
carrying the EJ5-GFP reporter were transfected with I-SceI expression plasmid and on the following day were treated with the indicated 
concentrations of MEB55 for 24 hr. GFP positive cells were quantified 24 hr later by FACS. Results represent mean ± SD from at least 
three independent experiments.
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µM. In contrast, the survival fraction of cells treated with 
2.5 ppm of MEB55 (just below the IC50 concentration: of 
2.7 ppm) alone was 60% ± 0.6 and together with 8 µM 
olaparib was reduced to 38% ± 1.0 (p ≤ 0.007). Similar 
results were obtained even in the presence of lower 
MEB55 concentrations (1.25 ppm, equivalent to IC23), at 
which the survival fraction of SLs-treated cells was 76% 
± 6.6 and in combination with 8 µM olaparib was further 
reduced to 53% ± 1.7 (p ≤ 0.005) (Figure 6E). Non-
linear regression analysis of the sigmoidal dose response 
revealed that IC50 values of olaparib were significantly 
reduced to 0.329 μM with 95% confidence interval (CI) 
(1.121-5.356 p ≤ 0.001, in the presence of MEB55 at 2.5 
ppm. 
The synergy between SLs and PARP inhibitors was 
calculated according to Kern, et al. [49] and Romaelli, et 
al. [50]. This method is suitable when one compound has 
no cytotoxic effect of its own. According to this method, 
the R index above 1 (1 = additive effect) indicates synergy. 
An R index of 2.7 was observed when cells were treated 
with the combination of olaparib and MEB55 (2.5 ppm). 
An R index of 2.2 was observed when cells were treated 
with veliparib and MEB55 (Supplementary Figure S8). At 
20 µM veliparib, the survival fraction of cells was reduced 
to 28.5% ± 9.3 (p ≤0.01) and was further reduced to 18% ± 
9.3 with 40 µM of veliparib (p ≤ 0.007). A similar synergy 
was also detected when the triple negative, breast cancer 
cells, MDA-MB-231, were treated with the combination 
of veliparib and MEB55 (Supplementary Figure S9). 
The combination of PARP inhibitors with SLs is highly 
synergistic with a remarkable loss of cell viability relative 
to each individual treatment. As expected, our previously 
published U34 cells (U2OS cells that are stably silenced 
for BRCA1) [51], are sensitive to olaparib. The R index 
for olaparib and MEB55 (IC50) is  0.56; for MEB55 (IC25) 
R = 0.72 and for MEB55 IC13 R = 1.0, indicating that 
MEB55 (IC50) combination with olaparib does not provide 
further sensitivity; an R index of 0.56 suggests that SLs 
(MEB55) target the HDR pathway and that BRCA1 is 
epistatic to SLs target. 
DISCUSSION
The results of this study show that the synthetic 
strigolactone analogs, MEB55 and ST362, induce G2/M 
cell cycle arrest and apoptosis of cancer cells [6, 7], 
which is accompanied by induction of DNA damage 
in the form of DSBs and inhibition of DSB repair. The 
increase in chromosome count following SLs treatment 
was visualized by metaphase spreads. The presence of 
DNA DSBs was visualized by the non-denaturing Comet 
assay and was further supported by the formation of 
nuclear γH2AX foci that mark DSBs. The phosphorylation 
of ATM and ATR kinases and their downstream effectors 
Chk1 and Chk2, as well as co-localization of 53BP1 
with γH2AX foci indicate that cells sense SLs-mediated 
DNA damage and activate the DNA damage response 
signaling. The failure of the homologous recombination 
repair protein, RAD51, to localize to γH2AX-marked 
damage sites and activate HDR indicates that SLs induce 
uncoupling between DNA damage signaling and DNA 
repair that could trigger cell death. The selectivity of SLs 
toward cancer cells was demonstrated by the very few 
nuclear γH2AX foci indicative of DSBs that were detected 
in normal BJ fibroblasts with no significant differences 
between SLs-treated and non-treated cells.
DSBs are the most deleterious form of DNA 
damage. Once DSBs are formed, cells can utilize either 
one or both of the two main pathways for DSBs repair: 
an error prone non-homologous end joining (NHEJ) or an 
error-free homology-directed repair (HDR) [11, 52]. HDR 
is critical for cell survival but the activity is restricted 
to cells in late S or G2 phases of the cell cycle. On the 
other hand, NHEJ is utilized by cells throughout the cell 
cycle [13, 52]. Here we report that HDR is significantly 
inhibited in a dose-dependent manner by SLs in cancer 
cells. Interestingly, NHEJ repair initially failed to be 
activated relative to untreated cells despite an increase 
in DNA-PKcs phosphorylation and the presence and 
persistence of DSBs. As SLs induce the G2/M arrest [6, 7], 
we speculate that the substantial loss of HDR has greater 
impact than loss of NHEJ on cell fate and SL-induced cell 
death. We propose a mechanism for sensitivity of cells to 
SLs due to defects in both HDR and NHEJ repair. 
Our current understanding of the molecular effects 
and targets of SLs is still limited. Our initial hypothesis 
that SLs could function as topoisomerase inhibitors based 
on their ability to induce DNA damage and inhibit DNA 
repair is not supported by our findings. DOX, one of 
the most widely used drugs in chemotherapy regimens, 
induces DNA DSBs by intercalating into the DNA and 
inhibiting DNA topoisomerase II. The interaction between 
SLs and DOX suggests that they do not act in a similar 
fashion. Furthermore, our direct biochemical assays 
clearly show that SLs do not intercalate into the DNA and 
do not inhibit topoisomerase activities. 
Our metaphase analyses show elevated chromosome 
counts in cancer cells treated with SLs. Chromosome 
breakage was observed in the highly sensitive FANCC 
cells; however, there was no indication for induction 
of DNA crosslinking that was further corroborated by 
metaphase spread analyses of FANCC cells. Overall, our 
data suggest that SLs may cause DSBs, impair HDR, and 
induce cancer cell death through a unique mode of action. 
Recent findings demonstrate that cancer cells and 
tumors deficient in HDR are highly sensitive to DNA 
damaging agents and PARP inhibitors by a mechanism of 
synthetic lethality [9]. This property has been successfully 
translated into the clinic for breast and ovarian cancer 
patients with mutations in the tumor suppressor genes, 
BRCA1 or BRCA2 [14, 53]. Due to HDR defects, these 
patients at least initially respond very well to PARP 
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Figure 6: SLs synergize with PARP inhibitors to reduce U2OS cancer cell viability. A. SLs do not intercalate into DNA and do 
not displace EtBr. Circular DNA was incubated with EtBr at 0.8 ug/mL for 1 hr before the indicated concentrations of MEB55 were added. 
The fluorescence intensity (I/I0) of samples was excited at 525 nm, and measured at 590 nm. B. Similar to (A) except DNA was resolved on 
a 0.8% agarose gel. C. Topoisomerase-I inhibition assays. The purified, end-labeled 117 bp nucleotide encompassing Top1 cleavage sites 
was incubated with recombinant Top1 enzyme in the presence of various concentrations of MEB55 (left) or ST362 (right). D. U2OS cells 
were seeded in 6 replicates into 96-well plates (2500/well) and their growth in response to 96 hr treatments with different concentrations of 
MEB55 and doxorubicin relative to vehicle-treated (DMSO) cells was analyzed by XTT assay. C-Index curve analysis (Chou and Talalay 
plot [46]) for DOX/SLs in U2OS indicates synergy [46] when C-Index values are less than 1 (the horizontal line that indicates the additive 
effect). Values greater than 1 indicate antagonism. To calculate the FA point DOX/SLs were mixed using constant ratios corresponding to 
0.25, 0.5, 1, 2, and 4 times the IC50 for each drug. Graph is representative of at least three independent experiments. E. U2OS cells were 
seeded into 96-well plates (2500/well) in 6 replicates and their growth in response to 96 hr treatments with different concentrations of 
MEB55 and olaparib relative to vehicle-treated (DMSO) cells was analyzed by crystal violet assay. Graph is representative of mean ± SD 
from at least three independent experiments. Data points are connected by non-linear regression of the sigmoidal dose-response. The IC50 
value of olaparib in the presence of MEB55 is 0.329 µM with 95% CI (1.121 -5.356). F. BRCA1-silenced U2OS, U34, [51] growth in 
response to MEB55 and olaparib was analyzed as in (E). An immunoblot is presented to confirm the loss of BRCA1 expression in U34, 
relative to parental U2OS and U2OS cells overexpressing BRCA1 as previously described [61].
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inhibitors [14]. 
RAD51 is an integral component of the cellular 
DNA damage response and a key factor for HDR [21, 34]. 
Its recruitment to DSB sites marked by γH2AX depends 
on BRCA2 and BRCA1 [54] and the quantification of 
RAD51 foci is well accepted as a marker of HDR activity 
[21, 34]. RAD51 expression is elevated in many human 
cancers including breast, prostate, lung and soft tissue 
sarcoma  [25, 29, 30, 55]. RAD51 overexpression is 
associated with an increase in DNA repair activity that 
could account for tumor's resistance to radiotherapy 
and DNA damaging chemotherapy [10, 25, 26]. Thus, 
targeting RAD51 could increase the effectiveness of 
cancer treatments. While disease-associated mutations 
in RAD51 are extremely rare, depletion by siRNA or 
miRNA induces a “BRCAness” phenotype and sensitizes 
cancer cells to DNA damaging agents such as cisplatin 
and PARP1 inhibitors similarly, to BRCA1 and BRCA2 
mutations [18, 23-25, 56]. 
Here we show a lack of distinct RAD51 nuclear 
foci in U2OS and DU145 cells despite the formation 
of γH2AX foci following SLs treatment. Furthermore, 
we demonstrate that RAD51 levels are down regulated 
by SLs via ubiquitination and proteasomal degradation, 
similar to the effect by another recently identified 
RAD51 inhibitor, IRB2 [22]. These findings imply that 
SLs target directly or indirectly RAD51 expression 
and function by interfering with RAD51 recruitment to 
DSB sites and hence with HDR. Given that BRCA1 is 
an E3 ubiquitin ligase activated by DNA damage [51], it 
would be interesting to identify the role SLs might play 
in modulating BRCA1 activity. Not surprisingly, our data 
show significant synergy between SLs and the PARP 
inhibitors, which inhibit base excision repair, in effectively 
killing U2OS cells. However, no synergy between SLs and 
PARP inhibitors was detected in the absence of BRCA1 
expression, further supporting a role for SLs in HDR 
inhibition. Notably, SLs do not induce DNA damage 
nor cause cell death in normal, non-transformed human 
fibroblasts, suggesting that SLs may be of important 
clinical relevance. The selectivity of SLs to cancer cells 
may result from a differentially expressed, yet unknown 
receptor for SLs in cancer cells. Alternatively, the genomic 
instability already present in cancer cells may render them 
hypersensitive to the DNA damaging effect of SLs. 
An important question that remains to be answered 
is whether SLs actions in mammalian cells resemble their 
mechanisms of action in plant cells. The receptor for SLs 
in plants was recently characterized as a heterodimer of 
an α/β-fold protein and an F-box protein (MAX2-More 
Axillary Growth 2). The F-box protein is a component of 
the SCF E3 ubiquitin ligase machinery and is responsible 
for recognizing and interacting with different substrates to 
result in their proteasomal degradation. Both proteins are 
present in the nucleus and the cytosol, and downstream 
events were recorded in both subcellular compartments [5, 
57]. In mammalian cells, the cellular reception of SLs is 
still unknown. Our previous studies suggested that SLs-
mediated signaling occurs at least partially in the nucleus 
as they are capable of altering cells’ transcriptional 
program [7] and can influence the expression and 
activity of both nuclear and cytoplasmic proteins [6, 7, 
58]. It is intriguing to speculate as to whether RAD51 
is a ubiquitination target of the SLs receptor. We are 
currently using biotinylated fluorescent SLs to identify 
the mammalian SLs receptor and their cellular destination. 
Finally, despite a large number of studies describing 
multiple signaling pathways that strigolactones utilize to 
regulate root and shoot development [59, 60], there are 
no reports on the role of strigolactones in maintenance of 
plant genome stability. It would be especially interesting 
to determine whether strigolactones suppress adventitious-
root formation or the outgrowth of pre-formed axillary 
buds in shoots via induction of DNA damage and 
manipulation of DNA repair as in cancer cells. 
MATERIALS AND METHODS
Cell culture, reagents and transfections
The human cell lines U2OS, DU145, MDA-
MB-231 and BJ fibroblasts were obtained from ATCC and 
Georgetown University tissue culture core facility. U2OS-
DR-GFP cells (a gift from M. Jasin, Memorial Sloan 
Kettering Cancer Center), were propagated in DMEM 
supplemented with 10% FBS. U2OS-EJ5-GFP cells (a gift 
from Dr. Jeremy Stark, City of Hope) were propagated as 
described [44]. All tissue culture media and serum were 
purchased from Gibco (Invitrogen), unless otherwise 
indicated. FANCC cells (GM13020) were purchased from 
Coriell Institute for Medical Research and maintained in 
suspension in RPMI-1640 supplemented with 15% FBS 
(HyClone Laboratories). 
Human prostate samples were collected under the 
auspices and approval of the Georgetown University 
and Sloan Kettering Institutional Review Boards. For 
PP8T cells, pathological analysis confirmed that all tissue 
sections collected were nearly exclusively tumor cells. 
The specimens were processed via protease dissociation 
as previously described [7, 39]. Primary cultures were 
established at Georgetown University Medical Center 
using the CRC method as previously described [7, 38, 
39]. For PCA3, cells from a prostate cancer organoid [38] 
were conditionally reprogrammed and  co-cultured in 
F-media supplemented with Y27632 and with irradiated 
J2 fibroblasts. For SL studies, the cells were cultured in 
conditioned media as described [41]. Briefly, irradiated J2 
feeder cells were plated in 175 cm2 tissue culture flasks 
(BD Biosciences, Franklin Lakes, NJ) in 30 ml of F media. 
The media was collected after three days in culture and 
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centrifuged at 1000 g for 5 minutes at 4°C to remove 
cellular debris, followed by filtration using a 0.22 µm 
Millex-GP filter unit (Millipore, Billerica, MA). For cell 
culture, three volumes of conditioned F media were mixed 
with one volume of fresh F medium and the final working 
conditioned media was supplemented with 5 µM Y-27632.
Strigolactone analogs, MG132 (Tocris), Olaparib 
and veliparib (Selleckchem) and Mitomycin C (ENZO) 
were dissolved in DMSO. Doxorubicin (Sigma) was 
dissolved in ethanol. Irradiation was performed as 
previously described [51]. Transfections of the I-SceI 
expression vector (pCBASce), empty vector (pCAGGS) 
or positive control (NZEGFP) were performed using 
Effectene (Qiagen) according to the manufacturer’s 
protocol. For BRCA1 overexpression, U2OS cells were 
infected with Ad-BRCA1 as previously described [61].
Cell cycle and apoptosis and caspase assays
Cells treated with vehicle or SLs were harvested, 
washed twice with 1 x PBS and then fixed in chilled 
ethanol (70%; v/v in PBS) with gentle vortex mixing. 
To determine their DNA contents, cells were stained 
with 40 µg/ml propidium iodide (PI) and analyzed using 
a FACSCalibur flow cytometer and CellQuest analysis 
software (Becton Dickinson, San Jose, CA). For apoptosis, 
cells were harvested and resuspended in 1 x Annexin V 
Binding Buffer (BD Biosciences, San Jose, CA, USA) 
prior to the addition of 2 µL FITC-Annexin V (BD 
Biosciences). Cells were stained with PI (40 µg/mL) and 
then analyzed by flow cytometry using a BD FACSCalibur 
flow cytometer. Cells were considered  apoptotic if they 
were Annexin V+/PI- (early apoptotic) or Annexin V+/
PI+ (late apoptotic). Each analysis was performed using 
at least 20,000 events. 
Caspase assay
U2OS cells were treated with 10 ppm of MEB55 
for the indicated durations. Samples were trypsinized 
and seeded (10,000 cells/well) into a white-bottom 96-
well plate (100 µL/well) and incubated with equivolume 
Caspase 3/7-Glo reagents for 30 min at RT. Luminescence 
was measured on a plate reader (Glomax, Promega). 
The absolute value of luminescence units was taken by 
subtracting blank wells of medium alone. The experiment 
was repeated at least three times and results represent the 
mean ± SD. 
Metaphase spread
U2OS cells were treated with vehicle or 10 ppm 
of MEB55 or ST362 for 5 hr. Colcemid (0.1 μg/ml) was 
added to the medium 1 hr before harvesting. Cells were 
trypsinized and cell pellets were washed with 1x PBS 
prior to the addition of hypotonic solution (0.8% sodium 
citrate). Cells were fixed in Carnoy’s fixative (3:1 absolute 
Methanol: glacial acetic acid) and then dropped onto 
glass slides, air-dried and stained with 4’,6-diamidino-
2-phenylindole (DAPI). Slides were imaged on the Zeiss 
Axiovert 200M microscope. Averages of chromosome 
counts of 20 cells per treatment were counted and 
statistically analyzed by an unpaired t -test compared to the 
untreated samples. FANCC cells were treated with 300 nM 
Mitomycin C or 10 ppm ST362 and MEB55 for three days 
and metaphase spreads were prepared according to the 
protocol previously described by Oostra AB, et al. [62].
Comet assay
The neutral Comet assay selectively tests for double-
strand breaks and was carried out using the Trevigen 
CometAssay Kit (Gaithersburg, MD) as previously 
described [63]. Following 4 hr treatment with vehicle or 10 
ppm MEB55, cells were harvested in ice-cold PBS, mixed 
with low melting agarose, and plated onto Comet slides at 
4°C. Slides were then placed in lysis solution overnight 
prior to electrophoresis in TBE buffer for 30 minutes at 
22V. Slides were washed with water and 70% ethanol 
and placed in an oven to dry. Comets were visualized 
following SYBR green staining under a fluorescent 
microscope at 494 nm. Analysis of the slides was done 
using the CometScore program (TriTek, Sumerduck, VA). 
Tail moment (calculated by CometScore) was used to 
quantify DNA damage.
Immunoblotting and Immunoprecipitation 
analysis
Immunoblot analysis was carried out as previously 
described [7]. Whole cell lysates were prepared and 
protein concentration was determined using the BCA 
Protein Assay (Pierce). Immunoblots were performed by 
incubation with the appropriate antibodies (Supplementary 
Table 1) for either 2 hr at room temperature or overnight 
at 4°C. Secondary antibodies were incubated for 30 min at 
room temperature, and proteins were visualized with West 
Pico Stable (ThermoScientific). For immunoprecipitation, 
U2OS cells were treated with 10 µM MG132 for 1 hr prior 
to treatment with either vehicle or 10 ppm of MEB55 for 
an additional 4 hr. Three mg of whole cell extracts from 
vehicle and MEB55-treated cells were incubated with anti-
RAD51 polyclonal and protein A/G beads and analyzed 
by immunoblot with either a monoclonal antibody against 
ubiquitin or against RAD51. Antibodies used in this study 
are described in Table S1. 
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Immunofluorescence analysis
Cells were seeded on coverslips 24 hr before 
treatment with SLs. At the indicated times, cells were 
treated with 0.7% Triton X-100 in Cytoskeletal buffer 
(10mM Hepes pH 7.0, 100mM NaCl, 300mM Sucrose, 
3mM MgCl2, 0.7% Triton X-100), then fixed with 
4% paraformaldehyde in PBS. The fixed cells were 
permeabilized using 0.1% Triton X-100 in PBS for 15 
min followed by blocking with 10% goat serum and then 
incubation with primary antibodies. The bound antibodies 
were revealed by Goat-anti-mouse IgG coupled to Alexa 
Fluor 488 (Life Technologies) and goat anti-rabbit 
coupled to Alexa 594 (Life Technologies). After washes, 
the coverslips were mounted to slides using Vectashield 
(Vector Laboratories).
Homology-directed repair assay
Homologous recombination was measured in DR-
GFP-U2OS cells as previously described [42]. Cells were 
transfected with pCBASceI (pCBAS), an empty vector 
(pCAGGS) or with pNZF-GFP as a positive control for 
GFP-positive cells. After 24 hr,  cells were treated with 
different concentrations of MEB55 for an additional 
24 hr and processed for flow cytometric analysis. For 
each analysis, 1×104 cells were analyzed. Each data 
point represents the mean ± SD from three independent 
experiments.
Non-homologous end joining (NHEJ) assay
The effect of SLs on NHEJ was analyzed via 
a U2OS EJ5-GFP reporter system [44]. Cells were 
transfected with pCBASce, an empty vector, pCAGGS, 
as a negative control or full-length GFP expression 
construct (NZF-GFP) as a positive control for GFP+ cells. 
On the next day, cells were treated with the indicated 
concentrations of ST362 and MEB55 and after an 
additional 24 hr, cells were processed for flow cytometric 
analysis. For each analysis, 1×104 cells were collected. 
Each data point represents the mean ± standard deviation 
from three independent experiments.
Topoisomerase-I-mediated DNA cleavage 
reactions
Human recombinant Top1 was purified from 
baculovirus as previously described [47]. DNA cleavage 
reactions were prepared as previously reported with the 
exception of the DNA substrate [64]. Briefly, a 117-bp 
DNA oligonucleotide (Integrated DNA Technologies) 
encompassing the previously identified Top1 cleavage sites 
in the 161-bp fragment from pBluescript SK(-) phagemid 
DNA was employed. This 117-bp oligonucleotide contains 
a single 5’-cytosine overhang, which was 3’ -end-labeled 
by fill-in reaction with [32P] dGTP in React 2 buffer (50 
mM Tris-HCl, pH 8.0, 100 mM MgCl2, 50 mM NaCl) 
with 0.5 units of DNA polymerase I (Klenow fragment, 
New England BioLabs). Unincorporated [32P] dGTP was 
removed using mini Quick Spin DNA columns (Roche, 
Indianapolis, IN), and the eluate containing the 3’ end-
labeled DNA substrate was collected. Approximately 2 
nM of radiolabeled DNA substrate was incubated with 
recombinant Top1 in 20 μL of reaction buffer [10 mM 
Tris-HCl (pH 7.5), 50 mM KCl, 5 mM MgCl2, 0.1 mM 
EDTA, and 15 μg/mL BSA] at 25 0C for 20 min in the 
presence of various concentrations of compounds. The 
reactions were terminated by adding SDS (0.5% final 
concentration) followed by the addition of two volumes of 
loading dye (80% formamide, 10 mM sodium hydroxide, 
1 mM sodium EDTA, 0.1% xylene cyanol, and 0.1% 
bromophenol blue). Aliquots of each reaction mixture 
were subjected to 20% denaturing PAGE. Gels were dried 
and visualized using a phosphoimager and ImageQuant 
software (Molecular Dynamics). For simplicity, cleavage 
sites were numbered as previously described in the 161-bp 
fragment [48]. 
Ethidium bromide displacement assay
EtBr is a well-known DNA intercalator, and its 
fluorescence intensity increases considerably after binding 
with DNA due to intercalation. The EtBr displacement 
assay was carried out as previously described [45]. Briefly, 
binding of an agent to DNA would displace the intercalated 
EtBr and subsequently quench the fluorescence caused by 
the EtBr-DNA complex. Before measurement, DNA (20 
μg/mL) was incubated with EtBr (0.8 μg/mL) for 1 hour. 
Different concentrationss of SLs were then titrated into the 
DNA-EtBr solution. The fluorescence intensity of samples 
was excited at 525 nm, and the fluorescence was measured 
at 590 nm at a temperature of 25oC using a GloMax+ 
microplate reader (Promega). Sample fluorescence was 
determined after subtracting the baseline fluorescence 
of EtBr in the absence of the DNA. The experiment was 
repeated three times and results represent mean ± SD. 
XTT viability assay 
Cells were seeded into a 96-well plates at 2500 cells 
per well in triplicates. On the following day, cells were 
treated with the indicated final concentrations of SLs or 
vehicle alone. Cells were incubated for 3 days, at which 
time XTT (2, 3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino)-carbonyl]-2H-tetrazolium inner 
salt) reduction was used to quantify viability according 
to manufacturer’s instructions (ATCC). Absorbance 
was recorded by Glomax-Multi Detection plate reader 
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(Promega) at 450 nm with 750 nm of reference wavelength 
and cell survival was analyzed as previously described [7]. 
Graph is representative of the mean ± SD of at least three 
independent experiments.
Crystal violet growth assays
U2OS cells were seeded at 2,500 cells per well 
in 6 replicates in 96-well plates. After 24 hr, cells were 
treated with MEB55, ST362 or vehicle (DMSO) at the 
indicated doses (1.25 to 10 µM) and in combination with 
Doxorubicin (Sigma). After 72 hr, cells were fixed and 
stained with crystal violet solution (0.5% crystal violet 
and 25% methanol in dH2O). Following extensive washing 
with distilled water, plates were air dried overnight. 
Sodium citrate solution (0.1 M) was used to solubilize 
bound crystal violet and optimal densities were measured 
at 560 nm (Glomax-Multi Detection plate reader, 
Promega). All survival fractions are relative to vehicle-
treated control cells. Graph is representative of the mean 
± SD of at least three independent experiments. 
Drug interactions
DOX and SLs drug mixtures for calculation 
of combination index (CI) values were prepared by 
twofold serial dilutions of working concentrations for 
doxorubicin and MEB55. Using non-constant ratios, 
two concentrations above and below the calculated IC50 
(corresponding to 0.25, 0.5, 1, 2 and 4 times the IC50 ) were 
added to cells in XTT assay. Each concentration was tested 
in 6 replicates and the results were confirmed in at least 
three independent experiments. For interaction between 
PARP inhibitors and MEB55, different concentrations of 
olaparib or veliparib were tested in the presence of MEB55 
IC50 and IC25. Experiments were repeated at least three 
times with six replicates each. The interaction between 
PARP inhibitors and MEB55 was analyzed according to 
Kern, et al. [50].
Statistical analysis
Results are presented as mean ± SD of replicate 
analyses and are either representative or inclusive of 
at least three independent experiments. All statistical 
analyses were performed using two-tailed Student’s t-tests 
in GraphPad PRISM 6 software. In all figures, significant 
differences between specified pair of conditions, as judged 
by t-test, are indicated using asterisks (*0.01 < P < 0.05; 
**0.001 < P < 0.01; ***0.0001 < P < 0.001). IC50 doses 
for SLs were calculated by interpolation of the sigmoidal 
dose response curves (Graphpad Prism 6.0 software).
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